Use of Regorafenib (Stivarga) in Advanced Colorectal Cancer
Description: Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of three abstracts that discussed the use of regorafenib (stivarga) in advanced colorectal cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract #3567: Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study
Abstract #3551: Hand–foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC)
Abstract #4078: Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis